Advertisement
Home »

Pembrolizumab and carboplatin plus docetaxel treatment regimens may provide options for patients with triple-negative breast cancer who are ineligible for anthracycline-based regimens

Nov 28, 2023

ABOUT THE EXPERTS

Advertisement
Advertisement